Immunosuppression in renal transplantation: Long-term clinical trial of a double versus triple therapy regimen

Summary: Sixty-nine renal allograft recipients were randomized to two immunosuppressive regimens: 35 patients received cyclosporine A and prednisolone (PC) while 34 patients received low dose cyclosporine A, prednisolone and short term azathioprine (PCA). the data of 66 patients (34 in PC and 32 in PCA groups) were analysed. the median follow-up periods were 62 months for the PC group and 60 months for the PCA group. There was no difference in graft survival between the two groups but five patients died in the PC group compared to none in the PCA group (graft survival: 88 vs 90% at 1 year and 82 vs 82% at 5 years, P = not significant at any time point; patient survival: 90 vs 100% at 1 year and 88 vs 100% at 5 years, P = 0.05 at 5 years). There was a trend for patients in the PCA group to develop earlier and more frequent rejections (not significant; P = 0.106 and P = 0.062, respectively). There were also more episodes of acute cyclosporine A nephrotoxicity and cytomegalovirus (CMV) infection in the PC group. the mean serum creatinine at 5 years was significantly higher in the PCA group when compared to the PC group (179.8 ± 76.5 μmol/L vs 154.7 ± 41.0 μmol/L; P =0.05). We found that both therapeutic regimens were effective in preventing renal allograft rejections. However, double therapy was associated with higher patient mortality secondary to infection. Patients on triple therapy, on the other hand, were more prone to develop rejections in the early post-transplant period and were associated with less favourable renal function in the long run.     

防治血吸虫病药物的研究Ⅳ.几个口服锑剂的合成

Wiley在1951年合成了一类毒性较低和口服有效的锑剂硫代水杨酸氯化锑化合物(Ⅰ),我们曾重复制备I_a及I_b,提供动物试验.文献曾报导氨基化合物的锑络合物对动物感染日本血吸虫病有口服疗效.综合文献的结果,我们考虑含有巯基的杂环化合物可能与锑形成较稳定的化合物,这样也许会减轻毒性及副作用,同时口服后可能易于掌握其肠胃道吸收规律,因此,我们用三氯化锑与2-甲基-1,3-二氮茚及2-巯基-1,3-硫氮茚分别在苯中加热,生成相应的含锑化合物Ⅱ及Ⅲ.其结构尚未能肯定.     

Purification and subunit structure studies of human placental threonyl-tRNA synthetase

Human threonyl-tRNA synthetase has been purified from full-term placenta over 5000-fold with a 13% overall yield by a combination of affinity chromatographic methods and conventional procedures. The product was apparently homogeneous by the criterion of sodium dodecyl sulfate-polyacrylamide gel electrophoresis. The purified enzyme catalyzed the esterification of ? 3500 nmol L-threonine to tRNA per min per mg of protein at 37°, corresponding to a molecular activity of ? 700/min. The apparent molecular weight of the native enzyme ranged from 210 000 to 220 000 by gel-filtration on Sephadex G-200, and was either ? 110 000 or 228 000 by sucrose gradient centrifugation for different preparations. Sodium dodecyl sulfate-polyacrylamide gel electrophoresis demonstrated a single band of molecular weight 85 000 or 115 000 for different preparations. These results suggest that human placental threonyl-tRNA synthetase has a subunit structure of the type α₂ with a subunit molecular weight of about 100 000. However, some other molecular forms with lower specific activity were also found to exist under certain conditions.